Start Forschung Abteilungen / AGs / Institute Psychiatrie und Psychotherapie Arbeitsgruppen AG Translationale Forschung in der Psychiatrie Publikationen

Publikationen: Translationale Psychoseforschung (TRiP)

Bumb JM, Enning F, Mueller JK, van der List T, Rohleder C, Findeisen P, Noelte I, Schwarz E, Leweke FM. Differential melatonin alterations in cerebrospinal fluid and serum of patients with major depressive disorder and bipolar disorder. Compr Psychiatry. 2016 68:34-9.
Leweke FM, Mueller JK, Lange B, Rohleder C. Therapeutic Potential of Cannabinoids in Psychosis. Biol Psychiatry. 2016 79(7):604-12. Epub 2015 Nov 28.
Mueller JK, Rohleder C, Leweke FM. What is the promise of nicotinergic compounds in schizophrenia treatment?. Future Med Chem. 2016 8(17):2009-2012. Epub 2016 Oct 14.
Rohleder C, Müller JK, Lange B, Leweke FM. Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence. Front Pharmacol. 2016 7:422.
Rohleder C, Wiedermann D, Neumaier B, Drzezga A, Timmermann L, Graf R, Leweke FM, Endepols H. The Functional Networks of Prepulse Inhibition: Neuronal Connectivity Analysis Based on FDG-PET in Awake and Unrestrained Rats. Front Behav Neurosci. 2016 10:148.
Severance EG, Gressitt KL, Stallings CR, Katsafanas E, Schweinfurth LA, Savage CL, Adamos MB, Sweeney KM, Origoni AE, Khushalani S, Leweke FM, Dickerson FB, Yolken RH. Candida albicans exposures, sex specificity and cognitive deficits in schizophrenia and bipolar disorder. NPJ Schizophr. 2016 2:16018.
Tomasik J, Schwarz E, Lago SG, Rothermundt M, Leweke FM, van Beveren NJ, Guest PC, Rahmoune H, Steiner J, Bahn S. Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients. Brain Behav Immun. 2016 52:178-86. Epub 2015 Nov 2.


Zentralinstitut für Seelische Gesundheit (ZI) - https://www.zi-mannheim.de